skip to content
Sensitization of Prostate Cancer Cells to Androgen Deprivation and Radiation Via Manipulation of the MDM2 Pathway Preview this item
ClosePreview this item
Checking...

Sensitization of Prostate Cancer Cells to Androgen Deprivation and Radiation Via Manipulation of the MDM2 Pathway

Author: Alan Pollack; FOX CHASE CANCER CENTER PHILADELPHIA PA.
Publisher: Ft. Belvoir Defense Technical Information Center APR 2006.
Edition/Format:   eBook : EnglishView all editions and formats
Database:WorldCat
Summary:
MDM2 is a feedback regulator of p53. We found that MDM2 is central to the apoptotic response of prostate cancer cells to radiotherapy (RT), androgen deprivation (AD) and RT+AD. In vitro measurements in androgen sensitive and insensitive cells revealed that antisense- MDM2 (AS-MDM2) significantly enhanced apoptosis and overall cell death (clonogen survival) in response to all of these treatments. An orthotopic model  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

 

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Material Type: Internet resource
Document Type: Internet Resource
All Authors / Contributors: Alan Pollack; FOX CHASE CANCER CENTER PHILADELPHIA PA.
OCLC Number: 227900996
Notes: The original document contains color images. All DTIC reproductions will be in black and white.
Description: 35 p.

Abstract:

MDM2 is a feedback regulator of p53. We found that MDM2 is central to the apoptotic response of prostate cancer cells to radiotherapy (RT), androgen deprivation (AD) and RT+AD. In vitro measurements in androgen sensitive and insensitive cells revealed that antisense- MDM2 (AS-MDM2) significantly enhanced apoptosis and overall cell death (clonogen survival) in response to all of these treatments. An orthotopic model using wild-type LNCaP cells injected into the prostates of nude mice corroborated the in vitro findings, particularly in terms of sensitization to AD. The mouse model involved determinations of growth inhibition through measurements of serum PSA and MRI-based tumor volume. Treatment with AS-MDM2+AD and AS-MDM2+AD+RT resulted in the greatest growth inhibition, compared to the other groups. We have also measured MDM2 expression using immunohistochemistry in men treated on Radiation Therapy Oncology Group trials 86-10 and 92-02. MDM2 overexpression was associated with a higher rate of distant metastasis and mortality, independent of conventional factors, treatment, Ki-67 and p53. We now have a method not only for identifying men at high risk of treatment failure, but also for selecting men who would have the greatest potential benefit from therapeutically targeting MDM2. Men in all prostate cancer risk groups should benefit.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


<http://www.worldcat.org/oclc/227900996>
library:oclcnum"227900996"
library:placeOfPublication
library:placeOfPublication
owl:sameAs<info:oclcnum/227900996>
rdf:typeschema:Book
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:bookFormatschema:EBook
schema:contributor
schema:contributor
schema:datePublished"2006"
schema:datePublished"APR 2006"
schema:description"MDM2 is a feedback regulator of p53. We found that MDM2 is central to the apoptotic response of prostate cancer cells to radiotherapy (RT), androgen deprivation (AD) and RT+AD. In vitro measurements in androgen sensitive and insensitive cells revealed that antisense- MDM2 (AS-MDM2) significantly enhanced apoptosis and overall cell death (clonogen survival) in response to all of these treatments. An orthotopic model using wild-type LNCaP cells injected into the prostates of nude mice corroborated the in vitro findings, particularly in terms of sensitization to AD. The mouse model involved determinations of growth inhibition through measurements of serum PSA and MRI-based tumor volume. Treatment with AS-MDM2+AD and AS-MDM2+AD+RT resulted in the greatest growth inhibition, compared to the other groups. We have also measured MDM2 expression using immunohistochemistry in men treated on Radiation Therapy Oncology Group trials 86-10 and 92-02. MDM2 overexpression was associated with a higher rate of distant metastasis and mortality, independent of conventional factors, treatment, Ki-67 and p53. We now have a method not only for identifying men at high risk of treatment failure, but also for selecting men who would have the greatest potential benefit from therapeutically targeting MDM2. Men in all prostate cancer risk groups should benefit."@en
schema:exampleOfWork<http://worldcat.org/entity/work/id/487383917>
schema:inLanguage"en"
schema:name"Sensitization of Prostate Cancer Cells to Androgen Deprivation and Radiation Via Manipulation of the MDM2 Pathway"@en
schema:numberOfPages"35"
schema:publisher
schema:url
schema:url<http://handle.dtic.mil/100.2/ADA455341>

Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.